This article is more than 5 years old. Information may no longer be current.

VIDEO: ODs should consider ocular surface effects of glaucoma agents

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

ORLANDO, Fla. – Medications can impact the ocular surface whether or not they contain preservatives, according to Rich Mangan, OD, FAAO; Mitch Ibach, OD, FAAO; and Scott Hauswirth, OD, FAAO, here at the American Academy of Optometry meeting.

Optometrists are in a perfect position to advocate for patients and inform them of alternative technology, they said.

Disclosures: Ibach reports he is a consultant/lecturer for Aerie and Glaukos, a speaker for Alcon and a consultant for Ocular Therapeutix. Hauswirth reports financial relationships with Allergan, BioTissue, Glaukos, Mentholatum, Shire and Sun. Mangan reports no relevant financial disclosures.